HyperuricemiaPhase 2NCT02344862
Study of FYU-981 in Hyperuricemia With or Without Gout
A Phase 2 study testing FYU-981 High dose, (Oral daily dosing for 8 weeks), FYU-981 Middle dose, (Oral daily dosing for 8 weeks) and FYU-981 Low dose, (Oral daily dosing for 8 weeks) in people with Hyperuricemia, run by Fuji Yakuhin Co., Ltd. at 1 site in Japan.
Trial summary
The purpose of this study is exploratory investigation of safety and efficacy (dose response and optimal dose according to the percent reduction from baseline in serum urate level at the final visit) of FYU-981 administered orally to hyperuricemic patients with and without gout for 8 weeks (dose-escalating initial… Read more about this study
- Who is it for?
- Ages 20 to 64 years
- Conditions the study is for
- Hyperuricemia
- What is being tested?
- FYU-981 High dose, (Oral daily dosing for 8 weeks), FYU-981 Middle dose, (Oral daily dosing for 8 weeks) and FYU-981 Low dose, (Oral daily dosing for 8 weeks)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteJapan
- Study dates
- Jan 2014to Sep 2014
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 64 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Hyperuricemic or gout patients
- Serum urate level:
- >= 7.0mg/dL in patients with history of gout, or >= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or >= 9.0mg/dL
Who cannot join
- Gouty arthritis within two weeks before start of study treatment
- Secondary hyperuricemia
- HbA1c: >= 8.4%
- Uric acid-overproduction type in the classification of hyperuricemia
- History of, clinically significant cardiac, hematologic and hepatic disease
- Kidney calculi or clinically significant urinary calculi
Show all 9Show fewer
- eGFR: < 60mL/min/1.73m^2
- Systolic blood pressure: >= 180 mmHg
- Diastolic blood pressure: >= 110 mmHg
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Exploratory Study of FYU-981 for Hyperuricemia With or Without Gout (Phase II (IIa) Study)
The purpose of this study is exploratory investigation of safety and efficacy (dose response and optimal dose according to the percent reduction from baseline in serum urate level at the final visit) of FYU-981 administered orally to hyperuricemic patients with and without gout for 8 weeks (dose-escalating initial period: 4 weeks followed by maintenance period: 4 weeks) by the method of randomized (dynamic allocation), placebo-controlled, double-blind, parallel group comparison.
- Conditions
- Hyperuricemia
- Being tested
- FYU-981 High dose, (Oral daily dosing for 8 weeks), FYU-981 Middle dose, (Oral daily dosing for 8 weeks), FYU-981 Low dose, (Oral daily dosing for 8 weeks), Placebo, (Oral daily dosing for 8 weeks)
- Medical subject headings
- Hyperuricemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FYU-981 High dose, (Oral daily dosing for 8 weeks)Drug
Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
FYU-981 Middle dose, (Oral daily dosing for 8 weeks)Drug
Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
FYU-981 Low dose, (Oral daily dosing for 8 weeks)Drug
Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
Placebo, (Oral daily dosing for 8 weeks)Drug
Subjects randomized to the placebo arm receive placebo.
| Study group | Role | What they receive |
|---|---|---|
| FYU-981 High dose | Active comparator | Not described Receives: Drug: FYU-981 High dose, (Oral daily dosing for 8 weeks) |
| FYU-981 Middle dose | Active comparator | Not described Receives: Drug: FYU-981 Middle dose, (Oral daily dosing for 8 weeks) |
| FYU-981 Low dose | Active comparator | Not described Receives: Drug: FYU-981 Low dose, (Oral daily dosing for 8 weeks) |
| Placebo | Placebo comparator | Not described Receives: Drug: Placebo, (Oral daily dosing for 8 weeks) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent reduction from baseline in serum urate level at the final visit
Measured: 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2015 (estimated)
- Study startJan 2014
- Primary completionJul 2014
- Study completionSep 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HyperuricemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fuji Yakuhin Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02344862
- Sponsor's protocol ID
- FYU-981-003
- Status last verified
- Jan 2015
- First submitted
- 18 Jan 2015
- Last updated
- 26 Jan 2015
- Results posted
- No
- Data monitoring committee
- No
Publications
Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study. Clin Exp Nephrol. 2020 Mar;24(Suppl 1):44-52. doi: 10.1007/s10157-019-01802-w. Epub 2019 Nov 21.
PubMed 31754882
Study at a glance
From the registry record, last updated by the sponsor on 26 Jan 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploratory Study of FYU-981 for Hyperuricemia With or Without Gout (Phase II (IIa) Study)
- ClinicalTrials.gov ID
- NCT02344862
- Acronym / sponsor ID
- FYU-981-003
- Conditions
- Hyperuricemia
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Fuji Yakuhin Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- Jan 2014
- Primary completion
- Jul 2014 (actual)
- Study completion
- Sep 2014 (actual)
- First posted
- 26 Jan 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is exploratory investigation of safety and efficacy (dose response and optimal dose according to the percent reduction from baseline in serum urate level at the final visit) of FYU-981 administered orally to hyperuricemic patients with and without gout for 8 weeks (dose-escalating initial period: 4 weeks followed by maintenance period: 4 weeks) by the method of randomized (dynamic allocation), placebo-controlled, double-blind, parallel group comparison.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| FYU-981 High dose | Active comparator | Drug: FYU-981 High dose, (Oral daily dosing for 8 weeks) |
| FYU-981 Middle dose | Active comparator | Drug: FYU-981 Middle dose, (Oral daily dosing for 8 weeks) |
| FYU-981 Low dose | Active comparator | Drug: FYU-981 Low dose, (Oral daily dosing for 8 weeks) |
| Placebo | Placebo comparator | Drug: Placebo, (Oral daily dosing for 8 weeks) |
Who may qualify
- Ages
- 20 to 64 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Hyperuricemic or gout patients
- Serum urate level:
- >= 7.0mg/dL in patients with history of gout, or >= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or >= 9.0mg/dL
Key exclusion criteria (9 listed)
- Gouty arthritis within two weeks before start of study treatment
- Secondary hyperuricemia
- HbA1c: >= 8.4%
- Uric acid-overproduction type in the classification of hyperuricemia
- History of, clinically significant cardiac, hematologic and hepatic disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FYU-981 High dose, (Oral daily dosing for 8 weeks)Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose. | Drug | FYU-981 High dose |
| FYU-981 Middle dose, (Oral daily dosing for 8 weeks)Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose. | Drug | FYU-981 Middle dose |
| FYU-981 Low dose, (Oral daily dosing for 8 weeks)Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose. | Drug | FYU-981 Low dose |
| Placebo, (Oral daily dosing for 8 weeks)Subjects randomized to the placebo arm receive placebo. | Drug | Placebo |
Primary outcome
Percent reduction from baseline in serum urate level at the final visit
Time frame: 8 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jan 2015.
- Derived from this study: PubMed 31754882Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study. Clin Exp Nephrol. 2020 Mar;24(Suppl 1):44-52. doi: 10.1007/s10157-019-01802-w. Epub 2019 Nov 21.
Related trials for Hyperuricemia
Active, not recruitingObservational study
Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
Hyperuricemia and MAFLD
RecruitingPhase 2
Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
Chronic Kidney Disease
RecruitingPhase 3
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Gout
RecruitingPhase 3
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
Tophaceous Gout
Not yet recruitingPhase 3
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout
Gout Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing FYU-981 High dose, (Oral daily dosing for 8 weeks), FYU-981 Middle dose, (Oral daily dosing for 8 weeks) and FYU-981 Low dose, (Oral daily dosing for 8 weeks) in people with Hyperuricemia, run by Fuji Yakuhin Co., Ltd. at 1 site in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Jan 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent reduction from baseline in serum urate level at the final visit (time frame: 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02344862, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2015.